In the StatesMAINE: New Law Requires Use of 340B and Greater Rebate Recovery More
MASSACHUSETTS: Montigny's Landmark Gift Ban Passes State Senate More
Massachusetts Docs To Lawmakers: No Gift Ban More
MARYLAND: Annapolis Passes Sweeping PBM Reforms - Bills Await Governor's Signature More
ALABAMA: Glaxo And Novartis Face Medicaid Fraud Lawsuit More
CALIFORNIA: CALPIRG Calls Out Pharma on Dubious Marketing Practices More California Dreaming: Pharma Evades Gift Rules More
LOUISIANA: AG Ends Pricing Suit Against Amgen More
WASHINGTON, DC: In Win for PBMs, Court Says Industry May Challenge DC Disclosure Law More
VIRGINIA: Legislators to Reconvene on Mental Health Drug Issue More |
Outrages of the WeekBenefit Managers Profit by Specialty Drug Rights More
Merck Wrote Drug Studies for Doctors More |
Pharma Watch
Health Care Industry Spent $445M on Federal Lobbying in 2007 More
Amgen Overload More
Drug Firms Employ Strategy Masters More
Glaxo Becomes Master of Reinventing Drugs More
Biological? Trying To Clip Pharma's Wings More
Pfizer Net Drops 18% As Rivals Strengthen More
Corporate Welfare Helped Pharma, But Not NJ More
|
Prices & Health Care Costs
7.82% Average Price Increase on Branded Drugs in 2007 More
Debate Over Costly Medication for Children More
Report: Average Drug Copay Decreased in 2007 Due to Increased Generic Use More
U.S. Wastes More Than Half of Health Spending More
When Drug Costs Soar Beyond Reach More
Drug Costs Rise as Economy Slides More
Co-Payments Soar for Drugs With High Prices More
|
Generics & Patent Policy
Pharmacies, CMS Skirmish Over Generic Pricing More
Generic Drugs' Quick, Simple Route to Market Has Many Roadblocks More
Coalition Releases Letter in Support of Follow-On Biologics More
How Generics Differ From Brand Names More
Seven Senators Urge Administration to Implement Law Lowering Prescription Drug Prices More
AstraZeneca Settles Ranbaxy Patent Suit More
Experts Look at Future of Generics More
Lawsuit Accuses GSK, Biovail Of Delaying Competition for Wellbutrin XL More
Epilepsy Battle in the War Between Brands and Generics More
|
PBM Watch
See also IN THE STATES Maryland PBM legislation and OUTRAGES OF THE WEEK on specialty drugs and PBMs
PBMs say Bills To Speed Part D Payments to Pharmacies Could
Limit Fraud Detection, Increase Costs More
Leveling the Playing Field in the Pharmacy Benefit Management Industry More |
|
Fraud & Abuse
Accuracy of Vytorin Meeting Minutes Questioned
More
Firm Ista Subpoenaed Over Anti-Inflammatory Drug More
|
Conflicts of Interest
Citing Ethics, Some Doctors Reject Industry Pay More
Grassley Seeks Investigation of Grants More
Schering-Plough Heart Association Connection More
University Will Scrutinize Professor For Conflicts More
|
Advertising & Marketing
Drugmakers To Spend $1B On Direct Marketing More
Opposition to Proposed Off-Label Promotion Guidelines Amid Allegations of 'Ghostwriting' More
FDA Says Pfizer Viagra Video Violates Ad Rules More
Internet vs. Sales Reps: Which Do Docs Prefer? More
Sen. Grassley Sends Letter To Merck Requesting Explanation of Recent JAMA Reports More
Drug Makers Push Easing Off-Label Rules More
Many Ads For Psych Meds Are Unsubstantiated More
Branded Drugmakers May Be Liable For Off-Label Use of Generic Product More
Drug Companies to Reveal Grant Practices More
Drug, Device Makers To Disclose Payments to Physicians, Medical Education Grants More
|
Medicare
Medicare Plans Affected by Rising Drug Costs More
HHS Appeals Decision That Requires Release of Medicare Physician Claims Data More
Part D Improved Access to Medications for Most Seniors, but Sickest Still Skip Pills Due to Cost More
|
Medicaid
House Panel Unanimously Approves Legislation To Block Implementation of Medicaid Rule Changes More
Report: Proposed Medicaid Cuts Could Cost Hospitals Millions More
|
Safety & Clinical Trials
Reports: Data on Vioxx Was Misused More
Third Circuit Says FDA Regulation Preempts State Failure-to-Warn Claims More
Panel's Bipartisan View: F.D.A. Is Underfinanced More
E-Records Not Always Accurate, Doctors Say More
Auditors Critique FDA on Foreign Inspections More
Drug Money & Prescribing For Better Outcomes More
FDA Triples Death Estimate Linked to Heparin More
New Jersey AG Is The Latest To Probe Vytorin More
Drug Safety Monitoring for the 21st Century More
FDA Releases Draft Plan To Enhance Drug Safety Capabilities More
Heparin Probe Highlights Challenges of Regulating Global Drugs Market More
Rise in Price of Heparin's Active Ingredient Was a Sign of Trouble More
U.S. Identifies Tainted Heparin in 11 Countries More
|
Confidentiality
Insurers, FDA Team Up to Find Problem Drugs More
Can Microsoft & Google Protect Health Records? More
Critics of HIPAA Say Law Is Too Lenient To Adequately Protect Patient Privacy More
Personal Health Record Advocates Suggest More Privacy, Security Measures Needed More
|
Editorials
The Dangers in Preemption More
Disclosure needed in Medicaid debate More
Opinions on the High-Cost Specialty Drugs More
|
